)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Arrowhead Pharmaceuticals (ARWR) investor relations material
Arrowhead Pharmaceuticals Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary6 Jan, 2026
Key study findings
Interim phase I/II studies of ARO-INHBE and ARO-ALK7 in obese volunteers, including those with type 2 diabetes, show robust, dose-dependent target knockdown and significant reductions in visceral and liver fat, especially when combined with tirzepatide.
ARO-INHBE monotherapy achieved up to 85% mean and 94% max reduction in activin E, with up to 15.6% reduction in visceral fat and 38.6% reduction in liver fat; combination with tirzepatide led to 9.4% weight loss and 23.2% visceral fat reduction at 16 weeks, outperforming tirzepatide alone.
ARO-ALK7 demonstrated up to 94% ALK7 mRNA knockdown and 14.1% placebo-adjusted visceral fat reduction after a single dose, marking the first human proof of siRNA-mediated gene silencing in adipocytes.
Both agents were well tolerated as monotherapy and in combination with tirzepatide, with most adverse events mild, no discontinuations due to adverse events, and no significant lab abnormalities.
Combination therapy is particularly promising for obese diabetics, a group with high unmet need and less response to GLP-1 therapies, with early data suggesting additive or synergistic benefits.
Study design and rationale
Phase 1/2a studies evaluated ARO-INHBE and ARO-ALK7 in obese adults, with and without type 2 diabetes, as monotherapy and in combination with tirzepatide.
Key endpoints included safety, pharmacokinetics, changes in serum Activin E, body composition, liver fat, and glycemic parameters.
Both studies fully enrolled single and multiple ascending dose cohorts, with ongoing expansion and planning for Phase 2b.
Mechanism of action and genetic validation
ARO-INHBE targets hepatic INHBE to reduce Activin E, which regulates adipose lipolysis and is linked to insulin resistance and visceral fat accumulation.
ARO-ALK7 silences ALK7 in adipocytes, a receptor that suppresses lipolysis; genetic variants in ALK7 are associated with lower obesity and diabetes risk.
Both are RNAi-based therapeutics leveraging gene silencing for obesity and metabolic disease.
How do candidates address GLP-1 therapy limitations?
Impact on Arrowhead's cardiometabolic pipeline?
What data is key for advancing to later phases?
What explains INHBE combo weight loss in diabetics?
Significance of ALK7 adipocyte knockdown proof?
Arrowhead's obesity asset development strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arrowhead Pharmaceuticals earnings date
44th Annual J.P. Morgan Healthcare Conference12 Jan, 2026
Next Arrowhead Pharmaceuticals earnings date
44th Annual J.P. Morgan Healthcare Conference12 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arrowhead Pharmaceuticals Inc develops therapies that leverage RNA interference (RNAi) to treat genetic diseases. Its pipeline targets conditions in areas such as liver disease, cardiovascular disease, and oncology. The company is headquartered in Pasadena, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage